Editorial: Tolerating Factor VIII: Novel Strategies to Prevent and Reverse Neutralizing Anti-FVIII Antibodies.
作者信息
Lacroix-Desmazes Sébastien, Pratt Kathleen P
机构信息
Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
出版信息
Front Immunol. 2021 Jan 25;11:639386. doi: 10.3389/fimmu.2020.639386. eCollection 2020.
Abstract
摘要
相似文献
1
Editorial: Tolerating Factor VIII: Novel Strategies to Prevent and Reverse Neutralizing Anti-FVIII Antibodies.社论：耐受凝血因子VIII：预防和逆转中和性抗FVIII抗体的新策略。
Front Immunol. 2021 Jan 25;11:639386. doi: 10.3389/fimmu.2020.639386. eCollection 2020.
2
Tolerating Factor VIII: Recent Progress.耐受因子 VIII：最新进展。
Front Immunol. 2020 Jan 10;10:2991. doi: 10.3389/fimmu.2019.02991. eCollection 2019.
3
Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies.凝血因子 VIII：免疫原性和免疫耐受策略的观点。
Front Immunol. 2020 Jan 17;10:3078. doi: 10.3389/fimmu.2019.03078. eCollection 2019.
4
Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.成年血友病A抑制物患者：使用单一FVIII/VWF产品成功诱导免疫耐受。
Haemophilia. 2014 Nov;20(6):e414-7. doi: 10.1111/hae.12521. Epub 2014 Oct 21.
5
[Origin and nature of the neutralizing immune response against therapeutic factor VIII].[针对治疗性凝血因子VIII的中和免疫反应的起源与本质]
Med Sci (Paris). 2020 Apr;36(4):341-347. doi: 10.1051/medsci/2020060. Epub 2020 May 1.
6
Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice.C1 结构域中暴露环的修饰可降低血友病 A 小鼠对因子 VIII 的免疫反应。
Blood. 2012 May 31;119(22):5294-300. doi: 10.1182/blood-2011-11-391680. Epub 2012 Apr 12.
7
B cell-activating factor modulates the factor VIII immune response in hemophilia A.B细胞活化因子调节A型血友病患者的凝血因子VIII免疫反应。
J Clin Invest. 2021 Apr 15;131(8). doi: 10.1172/JCI142906.
8
Inhibitors in haemophilia A: the role of VWF/FVIII concentrates--a meeting report.甲型血友病中的抑制剂：血管性血友病因子/凝血因子VIII浓缩物的作用——会议报告
Haemophilia. 2009 Mar;15(2):587-91. doi: 10.1111/j.1365-2516.2008.01944.x.
9
Inhibitory antibodies in hemophilia A.血友病 A 中的抑制性抗体。
Curr Opin Hematol. 2012 Sep;19(5):399-405. doi: 10.1097/MOH.0b013e328356ed37.
10
Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?治疗性因子 VIII 的致病性免疫反应：加剧的反应还是耐受诱导失败？
Haematologica. 2019 Feb;104(2):236-244. doi: 10.3324/haematol.2018.206383. Epub 2018 Dec 4.
引用本文的文献
1
Determination of Rutin's antitumoral effect on EAC solid tumor by AgNOR count and PI3K/AKT/mTOR signaling pathway.通过 AgNOR 计数和 PI3K/AKT/mTOR 信号通路测定芦丁对 EAC 实体瘤的抗肿瘤作用。
Med Oncol. 2023 Mar 27;40(5):131. doi: 10.1007/s12032-023-01999-7.
本文引用的文献
1
ITI Treatment is not First-Choice Treatment in Children with Hemophilia A and Low-Responding Inhibitors: Evidence from a PedNet Study.ITI 治疗不是低反应性抑制剂血友病 A 儿童的首选治疗方法：来自 PedNet 研究的证据。
Thromb Haemost. 2020 Aug;120(8):1166-1172. doi: 10.1055/s-0040-1713097. Epub 2020 Jun 22.
2
Factor VIII replacement is still the standard of care in haemophilia A.VIII 因子替代疗法仍然是 A 型血友病的标准治疗方法。
Blood Transfus. 2019 Nov;17(6):479-486. doi: 10.2450/2019.0211-19. Epub 2019 Dec 11.
3
New therapies for hemophilia.血友病的新疗法。
Blood. 2019 Jan 31;133(5):389-398. doi: 10.1182/blood-2018-08-872291. Epub 2018 Dec 17.
4
The socioeconomic burden of patients affected by hemophilia with inhibitors.患有血友病抑制剂患者的社会经济负担。
Eur J Haematol. 2018 Oct;101(4):435-456. doi: 10.1111/ejh.13108. Epub 2018 Jul 27.
5
A cold-blooded view of adaptive immunity.冷血的适应性免疫观。
Nat Rev Immunol. 2018 Jul;18(7):438-453. doi: 10.1038/s41577-018-0003-9.
6
Beyond binding: antibody effector functions in infectious diseases.超越结合：传染病中的抗体效应功能。
Nat Rev Immunol. 2018 Jan;18(1):46-61. doi: 10.1038/nri.2017.106. Epub 2017 Oct 24.
7
Signaling by Antibodies: Recent Progress.抗体信号传导：最新进展
Annu Rev Immunol. 2017 Apr 26;35:285-311. doi: 10.1146/annurev-immunol-051116-052433.
8
Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX.血友病伴 VIII/IX 因子抑制剂患者出血的治疗与预防
J Clin Med. 2017 Apr 17;6(4):46. doi: 10.3390/jcm6040046.
9
The burden of inhibitors in haemophilia patients.血友病患者中抑制剂的负担。
Thromb Haemost. 2016 Aug 31;116 Suppl 1:S10-7. doi: 10.1160/TH16-01-0049. Epub 2016 Aug 16.
10
Antibody polyreactivity in health and disease: statu variabilis.抗体的多反应性在健康和疾病中的作用：变化不定的状态。
J Immunol. 2013 Aug 1;191(3):993-9. doi: 10.4049/jimmunol.1300880.
Zotero 插件